Durante-Mangoni et al (7) stated that the prevalence of anti-tTG IgA in HCV patients treated with IFN was 24% in those with CD symptoms, while it was 0.6% in others; furthermore, all IgA positive patients in their study had a histologically proven CD, so they hypothesized that INF therapy could trigger CD symptoms in silent patients, and that those symptoms were related to anti-tTG IgA positivity before treatment. The gene discussed is CD79A; the disease is Cowden disease.